Hyperthermic treatment at 56 °C induces tumour-specific immune protection in a mouse model of prostate cancer in both prophylactic and therapeutic immunization regimens.

Francesco De Sanctis,Sara Sandri,Matteo Martini,Marta Mazzocco,Alessandra Fiore,Rosalinda Trovato,Stefano Garetto,Davide Brusa,Stefano Ugel,Silvia Sartoris

Vaccine（2018）

Cited 11|Views23

No score

Abstract

•56 °C hyperthermia of TRAMP-C2 tumour cells (56°T-C2) induces DAMP secretion.•Preventive vaccination with 56°T-C2-pulsed DCs improves tumour protection.•Only docetaxel plus 56°T-C2-pulsed DCs therapeutic vaccination delays tumour growth.

Translated text

Key words

Hyperthermia,Dendritic cells vaccines,Docetaxel,Prostate carcinoma

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined

Hyperthermic treatment at 56 °C induces tumour-specific immune protection in a mouse model of prostate cancer in both prophylactic and therapeutic immunization regimens.

Hyperthermic treatment at 56 °C induces tumour-specific immune protection in a mouse model of prostate cancer in both prophylactic and therapeutic immunization regimens.